Literature DB >> 2696902

Prenatal narcotic exposure: perinatal and developmental effects.

K A Kaltenbach1, L P Finnegan.   

Abstract

Infants prenatally exposed to narcotics become passively addicted in-utero and may undergo neonatal abstinence at birth. Methadone maintenance in conjunction with intensive prenatal care for pregnant narcotic dependent women can reduce the incidence of intrauterine death, neonatal death, prematurity and its concomitant problems. However, methadone exposed infants have consistently been found to have smaller birthweights and head circumference than non-drug exposed infants. Although neonatal abstinence can be treated successfully with pharmacotherapy, the effects of in-utero narcotic exposure in the developing central nervous system are not fully understood. Infants exposed to narcotics in-utero have been found to have slit-like ventricles with smaller lateral ventricle and intracranial hemidiameter measurements during the first month of life. The incidence of strabismus is also greater in infants exposed to narcotics in-utero than the general population, but this appears to be related to lower birth weight, rather than a direct consequence of narcotic exposure. There does not appear to be developmental sequelae associated with prenatal narcotic exposure. After abstinence has abated, infants function well within the normal range of development during the first two years of life, although developmental scores may be lower than non-drug exposed comparisons groups. There are a myriad of confounding medical, pharmacological and environmental variables within this population and the relative importance of prenatal narcotic exposure in a continuum of risk factors needs to be more clearly delineated before the etiology of perinatal and developmental effects can be determined.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2696902

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  11 in total

1.  kappa-opioid receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative effect of opioids.

Authors:  J A Gurwell; M J Duncan; K Maderspach; A Stiene-Martin; R P Elde; K F Hauser
Journal:  Brain Res       Date:  1996-10-21       Impact factor: 3.252

Review 2.  Prenatal substance abuse: short- and long-term effects on the exposed fetus.

Authors:  Marylou Behnke; Vincent C Smith
Journal:  Pediatrics       Date:  2013-02-25       Impact factor: 7.124

3.  The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment.

Authors:  Christine Kreitinger; Hilda Gutierrez; Ajna Hamidovic; Cheryl Schmitt; Preeyaporn Sarangarm; William F Rayburn; Lawrence Leeman; Ludmila N Bakhireva
Journal:  J Matern Fetal Neonatal Med       Date:  2015-03-23

4.  Mu-opioid receptors modulate the stability of dendritic spines.

Authors:  Dezhi Liao; Hang Lin; Ping Yee Law; Horace H Loh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-19       Impact factor: 11.205

5.  Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes.

Authors:  L M Jansson; J A Di Pietro; A Elko; E L Williams; L Milio; M Velez
Journal:  Drug Alcohol Depend       Date:  2011-10-29       Impact factor: 4.492

6.  Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome.

Authors:  Teresa R Gray; Robin E Choo; Marta Concheiro; Erica Williams; Andrea Elko; Lauren M Jansson; Hendreé E Jones; Marilyn A Huestis
Journal:  Addiction       Date:  2010-09-20       Impact factor: 6.526

7.  Morphine inhibits Purkinje cell survival and dendritic differentiation in organotypic cultures of the mouse cerebellum.

Authors:  K F Hauser; J A Gurwell; C S Turbek
Journal:  Exp Neurol       Date:  1994-11       Impact factor: 5.330

8.  Development and implementation of a pharmacist-managed, neonatal and pediatric, opioid-weaning protocol.

Authors:  Melissa R Johnson; David R Nash; Mary R Laird; Robert C Kiley; Michael A Martinez
Journal:  J Pediatr Pharmacol Ther       Date:  2014-07

9.  Neuropsychological screening of children of substance-abusing women attending a Special Child Welfare Clinic in Norway.

Authors:  Bjørg Hjerkinn; Morten Lindbaek; Idar Skogmo; Elin Olaug Rosvold
Journal:  Subst Abuse Treat Prev Policy       Date:  2010-07-20

10.  Pharmacological treatment of neonatal opiate withdrawal: between the devil and the deep blue sea.

Authors:  Anthony Liu; Tracey Björkman; Caroline Stewart; Ralph Nanan
Journal:  Int J Pediatr       Date:  2011-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.